These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17687137)

  • 21. Rituximab therapy in severe juvenile pemphigus vulgaris.
    Mamelak AJ; Eid MP; Cohen BA; Anhalt GJ
    Cutis; 2007 Oct; 80(4):335-40. PubMed ID: 18038698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
    Carvalho R; Maio P; Cunha D; Freitas I; Afonso A; Cardoso J
    Eur J Dermatol; 2011; 21(3):415-6. PubMed ID: 21527367
    [No Abstract]   [Full Text] [Related]  

  • 24. Childhood pemphigus vulgaris successfully treated with rituximab.
    Kanwar AJ; Sawatkar GU; Vinay K; Hashimoto T
    Indian J Dermatol Venereol Leprol; 2012; 78(5):632-4. PubMed ID: 22960821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rituximab in pemphigus.
    Kanwar AJ; Vinay K
    Indian J Dermatol Venereol Leprol; 2012; 78(6):671-6. PubMed ID: 23075635
    [No Abstract]   [Full Text] [Related]  

  • 27. Delayed response of oral pemphigus vulgaris to rituximab treatment.
    Niedermeier A; Wörl P; Barth S; Schuler G; Hertl M
    Eur J Dermatol; 2006; 16(3):266-70. PubMed ID: 16709491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in severe pemphigus.
    Schmidt E; Goebeler M; Zillikens D
    Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update.
    Arin MJ; Hunzelmann N
    Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment with rituximab of autoimmune disease: results from AADEA's registry].
    Callejas Rubio JL; Camps MT; García-Hernández F;
    Med Clin (Barc); 2008 Jan; 130(2):79. PubMed ID: 18221681
    [No Abstract]   [Full Text] [Related]  

  • 31. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients.
    Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM
    Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of refractory pemphigus erythematosus with rituximab.
    Diab M; Bechtel M; Coloe J; Kurtz E; Ranalli M
    Int J Dermatol; 2008 Dec; 47(12):1317-8. PubMed ID: 19126029
    [No Abstract]   [Full Text] [Related]  

  • 33. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
    Kong HH; Prose NS; Ware RE; Hall RP
    Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab.
    Tournadre A; Amarger S; Joly P; d'Incan M; Ristori JM; Soubrier M
    Joint Bone Spine; 2008 Dec; 75(6):728-9. PubMed ID: 18455465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab in refractory autoimmune bullous diseases.
    Schmidt E; Hunzelmann N; Zillikens D; Bröcker EB; Goebeler M
    Clin Exp Dermatol; 2006 Jul; 31(4):503-8. PubMed ID: 16716150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of recalcitrant pemphigus foliaceus with rituximab.
    Serrão VV; Martins A; Páris FR; Lopes MP
    J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):768-70. PubMed ID: 18482042
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-lasting remission of pemphigus vulgaris treated with rituximab.
    Esposito M; Capriotti E; Giunta A; Bianchi L; Chimenti S
    Acta Derm Venereol; 2006; 86(1):87-9. PubMed ID: 16586007
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and biological activity of rituximab in the treatment of pemphigus.
    Bohelay G; Caux F; Musette P
    Immunotherapy; 2021 Jan; 13(1):35-53. PubMed ID: 33045883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab in refractory pemphigus vulgaris.
    Sorce M; Aricò M; Bongiorno MR
    Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapies for systemic lupus erythematosus: cellular targets.
    Looney RJ; Anolik J; Sanz I
    Rheum Dis Clin North Am; 2006 Feb; 32(1):201-15, xi. PubMed ID: 16504831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.